Healthcare / Medical DistributionSaudi
$2.53
-0.42 (-14.24%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-3.7M · quality 44.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
41/100
C
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$137M
P/E
50.6x
↑EV/EBITDA
13.4x
↑ROE
4.1%
↑Gross Margin
22.6%
↓Debt/Equity
0.45
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+31.3%
FCF CAGR
—
FCF margin
-11.2%
FCF / Net income
-3.85x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $92.3M · net income $2.7M · FCF $-10.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $92.3M | $92.3M | $84.1M | $48.6M | $40.8M |
| Net Income | $2.7M | $2.7M | $12.5M | $-1.9M | $5.5M |
| EBITDA | $12.0M | $12.0M | $17.7M | $1.8M | $6.9M |
| EPS | — | — | 0.23 | 0.04 | 0.10 |
| Gross Margin | 22.6% | 22.6% | 29.6% | 39.5% | 46.3% |
| Operating Margin | 7.5% | 7.5% | 10.6% | 0.6% | 16.1% |
| Net Margin | 2.9% | 2.9% | 14.8% | -4.0% | 13.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.45 | 0.45 | 0.25 | 0.03 | 0.03 |
| Current Ratio | 1.58 | 1.58 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-10.4M | $-10.4M | $-3.7M | $-2.6M | $5.6M |
| Returns | |||||
| ROE | 4.1% | 4.1% | 20.4% | -2.8% | 11.6% |
| Valuation | |||||
| P/E | 50.60 | 50.60 | 12.45 | 55.56 | — |
| EV/EBITDA | 13.40 | 13.40 | 9.25 | 48.50 | — |
| P/B | 2.10 | 2.10 | 2.53 | 1.56 | — |
| Growth & Yield | |||||
| Revenue Growth | 9.8% | 9.8% | 72.9% | 19.2% | — |
| EPS Growth | — | — | 447.6% | -58.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-12.8%
Start / end P/E
n/dx → n/dx
EPS bridge
0.23 → n/d
Residual
-12.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.